Drug Type Monoclonal antibody |
Synonyms BMS 986406, BMS-986406, BMS986406 |
Target |
Action inhibitors |
Mechanism LILRB2 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Malignant Neoplasm | Phase 1 | United States | 31 Mar 2022 | |
Locally Advanced Malignant Neoplasm | Phase 1 | Japan | 31 Mar 2022 | |
Locally Advanced Malignant Neoplasm | Phase 1 | Argentina | 31 Mar 2022 | |
Locally Advanced Malignant Neoplasm | Phase 1 | Belgium | 31 Mar 2022 | |
Locally Advanced Malignant Neoplasm | Phase 1 | Spain | 31 Mar 2022 |